A5008188983- Influenza Virus Research Studies
- Respiratory viral infections research
- SARS-CoV-2 and COVID-19 Research
- Monoclonal and Polyclonal Antibodies Research
- Immune Response and Inflammation
- Complement system in diseases
- COVID-19 Clinical Research Studies
- Neonatal Respiratory Health Research
- Malaria Research and Control
- Viral gastroenteritis research and epidemiology
- Mosquito-borne diseases and control
- Immunotherapy and Immune Responses
- Viral Infections and Outbreaks Research
- Hepatitis B Virus Studies
- Animal Virus Infections Studies
- Pneumonia and Respiratory Infections
- Vaccine Coverage and Hesitancy
- Animal Disease Management and Epidemiology
- vaccines and immunoinformatics approaches
- Parvovirus B19 Infection Studies
- SARS-CoV-2 detection and testing
- Blood groups and transfusion
- Immune Cell Function and Interaction
- Transgenic Plants and Applications
- Bacterial Infections and Vaccines
Novavax (United States)
2016-2025
University Hospital Frankfurt
2024
Goethe University Frankfurt
2024
Jenner Institute
2022
Oxford BioMedica (United Kingdom)
2022
University of Oxford
2022
Novavax (Sweden)
2022
Serum Institute of India (India)
2022
Institut de Recherche en Sciences de la Santé
2022
Center for Global Health
2021
NVX-CoV2373 is a recombinant severe acute respiratory syndrome coronavirus 2 (rSARS-CoV-2) nanoparticle vaccine composed of trimeric full-length SARS-CoV-2 spike glycoproteins and Matrix-M1 adjuvant.We initiated randomized, placebo-controlled, phase 1-2 trial to evaluate the safety immunogenicity rSARS-CoV-2 (in 5-μg 25-μg doses, with or without adjuvant, observers unaware trial-group assignments) in 131 healthy adults. In 1, vaccination comprised two intramuscular injections, 21 days apart....
Abstract The COVID-19 pandemic continues to spread throughout the world with an urgent need for a safe and protective vaccine effectuate herd protection control of SARS-CoV-2. Here, we report development SARS-CoV-2 subunit (NVX-CoV2373) from full-length spike (S) protein that is stable in prefusion conformation. NVX-CoV2373 S form 27.2-nm nanoparticles are thermostable bind high affinity human angiotensin-converting enzyme 2 (hACE2) receptor. In mice, low-dose saponin-based Matrix-M adjuvant...
Respiratory syncytial virus (RSV) is the dominant cause of severe lower respiratory tract infection in infants, with most cases concentrated among younger infants.
Group A streptococcus (GAS) causes illness ranging from uncomplicated pharyngitis to life-threatening necrotizing fasciitis, toxic shock, and rheumatic fever. Attempts develop an M protein-based vaccine have been hindered by the fact that some proteins elicit both protective antibodies cross-react with human tissues. New molecular techniques allowed previous obstacles be largely overcome.The is comprised of 4 recombinant adsorbed aluminum hydroxide contain N-terminal peptides streptococcal...
This study describes the safety and immunogenicity of a liposome-based vaccine injected into human subjects. Thirty healthy adult male volunteers were immunized with liposome-encapsulated recombinant protein (R32NS181) containing epitopes from repeat region circumsporozoite Plasmodium falciparum. antigen had previously been found to be poorly immunogenic in humans when it was adsorbed Al(OH)3. In present study, R32NS181 encapsulated liposomes monophosphoryl lipid A that subsequently...
Mammalian cells in culture express membrane receptors for C3b when infected with HSV-1. binding is mediated by glycoprotein C (gC), a virus-specified glycoprotein. In view of the inhibitory functions other C3b-binding proteins, we studied capacity gC to modulate complement activation. Glycoprotein was purified from HSV-1-infected immunoaffinity chromatography. C, but not control viral glycoprotein, demonstrated dose-dependent acceleration decay C3bBb sites. addition, produced dose-dependent,...
Background. Respiratory syncytial virus (RSV) is a leading cause of infant morbidity and mortality. A recombinant RSV fusion protein nanoparticle vaccine (RSV F vaccine) candidate for maternal immunization was tested safety immunogenicity in women childbearing age.
The recent emergence of severe human illness caused by avian-origin influenza A(H7N9) viruses in China has precipitated a global effort to rapidly develop and test vaccine candidates. To date, non-A(H7N9) H7 subtype candidates have been poorly immunogenic difficulties production virus seed strains encountered. A candidate recombinant consisting full length, unmodified hemagglutinin (HA) neuraminidase (NA) from the A/Anhui/1/2013 matrix 1 (M1) protein A/Indonesia/05/2005 (H5N1) were cloned...
Respiratory syncytial virus (RSV) causes significant morbidity and mortality in infants. We are developing an RSV fusion (F) protein nanoparticle vaccine for immunization of third trimester pregnant women to passively protect infants through transfer RSV-specific maternal antibodies. The present trial was performed assess the immunogenicity safety several formulations F 1-dose or 2-dose schedules. Placebo, with 60 μg 120 0.2, 0.4, 0.8 mg aluminum, were administered intramuscularly on Days 0...
Respiratory syncytial virus (RSV) is the leading cause of infant lower respiratory tract disease and hospitalization worldwide.
Abstract Background The recombinant protein-based vaccine, NVX-CoV2373, demonstrated 89.7% efficacy against coronavirus disease 2019 (COVID-19) in a phase 3, randomized, observer-blinded, placebo-controlled trial the United Kingdom. protocol was amended to include blinded crossover. Data end of are reported. Methods Adults aged 18–84 years received 2 doses NVX-CoV2373 or placebo (1:1) and were monitored for virologically confirmed mild, moderate, severe COVID-19 (onset from 7 days after...
NVX-CoV2373 is an adjuvanted recombinant full-length SARS-CoV-2 spike trimer protein vaccine demonstrated to be protective against COVID-19 in efficacy trials. Here we demonstrate that vaccinated individuals made CD4+ T cell responses after 1 and 2 doses of NVX-CoV2373, a subset CD8+ responses. Characterization the vaccine-elicited cells IFN-γ production. revealed both circulating follicular helper (cTfh) Th1 (IFN-γ+, TNF-α+, IL-2+) were detectable within 7 days primary immunization....
Seasonal influenza imposes a substantial personal morbidity and societal cost burden. Vaccination is the major strategy for prevention; however, because antigenically drifted A B viruses circulate annually, vaccines must be updated to provide protection against predicted prevalent strains next season. The aim of this study was assess efficacy, safety, reactogenicity, immunogenicity trivalent inactivated split virion vaccine (TIV) in healthy adults over two seasons US. primary endpoint...
Background. The tocopherol-based oil-in-water emulsion adjuvant system family (AS03) improves antigen sparing with split-virion H5N1 influenza vaccines, representing an important development for pandemic preparedness. In this phase 1/2 randomized, controlled, observer-blinded study in 680 adults, we assessed the immunogenicity and safety of A/Indonesia/5/05 (IBCDC-RG2, clade 2.1) prepandemic candidate vaccines produced at 2 separate manufacturing sites. Methods. Two doses, each which...
A preventative strategy for Respiratory Syncytial Virus (RSV) infection constitutes an under-recognized unmet medical need among older adults. Four formulations of a novel recombinant RSV F nanoparticle vaccine (60 or 90 μg protein, with without aluminum phosphate adjuvant) administered concurrently licensed inactivated trivalent influenza (TIV) in adult subjects were evaluated safety and immunogenicity this randomized, observer-blinded study. total 220 healthy males females ≥ 60 years age,...
Abstract The COVID-19 pandemic continues to spread throughout the world with an urgent need for a safe and protective vaccine effectuate herd immunity control of SARS-CoV-2. Here, we report development SARS-CoV-2 subunit (NVX-CoV2373) produced from full-length spike (S) protein, stabilized in prefusion conformation. Purified NVX-CoV2373 S form 27.2nm nanoparticles that are thermostable bind high affinity human angiotensin-converting enzyme 2 (hACE2) receptor. In mice baboons, low-dose...
Significance Strategies to reduce consumption of antimicrobial drugs are needed contain the growing burden resistance. Respiratory syncytial virus (RSV) is a prominent cause upper and lower respiratory tract infections, as single agent in conjunction with bacterial pathogens, may thus contribute both inappropriately treated viral infections appropriately polymicrobial involving bacteria. In double-blind, randomized, placebo-controlled trial, administering an RSV vaccine pregnant mothers...